Mersana Therapeutics (NASDAQ:MRSN) Trading Up 2.7%

Mersana Therapeutics, Inc. (NASDAQ:MRSNGet Free Report)’s share price rose 2.7% on Monday . The stock traded as high as $1.97 and last traded at $1.88. Approximately 1,278,267 shares changed hands during trading, a decline of 35% from the average daily volume of 1,981,425 shares. The stock had previously closed at $1.83.

Analyst Upgrades and Downgrades

Separately, JPMorgan Chase & Co. raised shares of Mersana Therapeutics from an “underweight” rating to a “neutral” rating and set a $5.00 price target on the stock in a research note on Tuesday, March 19th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to, the company presently has an average rating of “Moderate Buy” and a consensus price target of $6.29.

Get Our Latest Research Report on MRSN

Mersana Therapeutics Stock Up 2.6 %

The stock has a market cap of $239.83 million, a price-to-earnings ratio of -1.72 and a beta of 1.54. The company has a current ratio of 3.51, a quick ratio of 3.51 and a debt-to-equity ratio of 0.72. The stock’s 50-day moving average price is $2.36 and its 200-day moving average price is $3.28.

Mersana Therapeutics (NASDAQ:MRSNGet Free Report) last released its quarterly earnings data on Thursday, May 9th. The company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.02. Mersana Therapeutics had a negative net margin of 352.01% and a negative return on equity of 260.65%. The firm had revenue of $9.25 million for the quarter, compared to the consensus estimate of $8.50 million. During the same quarter in the prior year, the company posted ($0.52) earnings per share. The business’s revenue was up 18.5% on a year-over-year basis. On average, sell-side analysts expect that Mersana Therapeutics, Inc. will post -0.6 earnings per share for the current year.

Institutional Investors Weigh In On Mersana Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the company. Vanguard Group Inc. boosted its holdings in Mersana Therapeutics by 0.6% in the first quarter. Vanguard Group Inc. now owns 6,274,370 shares of the company’s stock valued at $28,109,000 after acquiring an additional 36,782 shares in the last quarter. Walleye Capital LLC raised its position in shares of Mersana Therapeutics by 1,205.0% in the 3rd quarter. Walleye Capital LLC now owns 2,021,467 shares of the company’s stock worth $2,567,000 after purchasing an additional 1,866,568 shares during the last quarter. ClariVest Asset Management LLC purchased a new position in Mersana Therapeutics in the 1st quarter worth about $2,114,000. Acadian Asset Management LLC raised its position in Mersana Therapeutics by 166.7% in the 1st quarter. Acadian Asset Management LLC now owns 468,923 shares of the company’s stock worth $2,099,000 after buying an additional 293,115 shares during the last quarter. Finally, Readystate Asset Management LP purchased a new position in Mersana Therapeutics in the 4th quarter worth about $684,000. 93.92% of the stock is owned by hedge funds and other institutional investors.

Mersana Therapeutics Company Profile

(Get Free Report)

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc, Ares Trading SA, Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates.

Featured Articles

Receive News & Ratings for Mersana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mersana Therapeutics and related companies with's FREE daily email newsletter.